Force Frequency Relationship of the Human Ventricle Increases During Early Postnatal Development

Rob F. Wiegerinck, Emory University
Anca Cojoc, Emory University
Carlo M. Zeidenweber, Emory University
Guoliang Ding, Emory University
Ming Shen, Emory University
Ronald Joyner, Emory University
Janet D. Fernández, Emory University
Kirk R Kanter, Emory University
Paul M. Kirshbom, Emory University
Brian Kogon, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Pediatric Research
Volume: Volume 65, Number 4
Publisher: Nature Publishing Group: Open Access Hybrid Model Option A | 2009-04, Pages 414-419
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1203/PDR.0b013e318199093c
Permanent URL: http://pid.emory.edu/ark:/25593/fhrht

Final published version:
http://www.nature.com/pr/journal/v65/n4/full/pr200980a.html

Copyright information:
© 2009 International Pediatric Research Foundation, Inc
Accessed January 23, 2020 10:34 AM EST
Force Frequency Relationship of the Human Ventricle Increases During Early Postnatal Development

Rob F. Wiegerinck, Anca Cojoc, Carlo M. Zeidenweber, Guoliang Ding, Ming Shen, Ronald W. Joyner, Janet D. Fernandez, Kirk R. Kanter, Paul M. Kirshbom, Brian E. Kogon, and Mary B. Wagner
Department of Pediatrics [R.F.W., A.C., C.M.Z., G.D., M.S., R.W.J., M.B.W.], and Department of Surgery [K.R.K., P.M.K., B.E.K.], Emory University, Atlanta, GA 30322; Children's Healthcare of Atlanta [J.D.F.], Atlanta, GA 30322

Abstract

Understanding developmental changes in contractility is critical to improving therapies for young cardiac patients. Isometric developed force was measured in human ventricular muscle strips from two age groups: newborns (<2 weeks) and infants (3–14 months) undergoing repair for congenital heart defects. Muscle strips were paced at several cycle lengths (CLs) to determine the force frequency response (FFR). Changes in Na/Ca exchanger (NCX), sarcoplasmic reticulum Ca-ATPase (SERCA) and phospholamban (PLB) were characterized. At CL 2000 ms, developed force was similar in the two groups. Decreasing CL increased developed force in the infant group to 131±8% (CL 1000 ms) and 157±18% (CL 500 ms) demonstrating a positive FFR. The FFR in the newborn group was flat. NCX mRNA and protein levels were significantly larger in the newborn than infant group whereas SERCA levels were unchanged. PLB mRNA levels and PLB/SERCA ratio increased with age. Immunostaining for NCX in isolated newborn cells showed peripheral staining. In infant cells, NCX was also found in T-tubules. SERCA staining was regular and striated in both groups. This study shows for the first time that the newborn human ventricle has a flat FFR, which increases with age and may be caused by developmental changes in calcium handling.

Keywords

Pediatric and congenital heart disease; Developmental biology; Contractile function; Heart failure - basic studies

Extrapolating pharmacological and surgical therapies from adult studies to pediatric patients is difficult since knowledge of contractility in the young human heart is limited, thus understanding developmental changes in excitation-contraction coupling is critical. In mammalian ventricle, contractility increases with postnatal development (1,2), but few studies have examined age-dependent effects on the force-frequency relationship (FFR). Several animal studies have found a positive FFR that is not changed with age (3,4). Direct studies of contractility of very young human ventricular strips are limited. Molenaar et al. (5) examined tension development in human ventricular strips from infants (2.5–35 months old) undergoing repair for tetralogy of Fallot (TOF) and report a positive FFR in their cohort. Recently, Cheung et al. (6) measured force frequency curves in children with congenital heart defects using tissue Doppler. They found that children with ventricular septal defects had a decreased force-rate.
trajectory after bypass surgery whereas neonates, undergoing arterial switch, had a greater
decrease of force-rate trajectory.

A flat or negative FFR is a characteristic feature of heart failure (7,8) and is associated
with changes in calcium handling proteins, including increased levels of Na/Ca exchanger (NCX)
(7,9) and decreased levels of sarcoplasmic reticulum (SR), calcium ATPase (SERCA),
phospholamban (PLB) and the PLB/SERCA ratio (10–12). NCX is significantly more
abundant in the newborn than the adult (1). Furthermore, SERCA is lower in newborn rabbit
(13,14) and PLB increases with postnatal age (2). In human ventricle, NCX mRNA and protein
levels decreased with age (15) whereas SERCA protein levels increased but mRNA levels were
unchanged (16). Alterations of these proteins can modify the ability of the SR to store calcium,
which may contribute to the blunted FFR.

We compared the response of newborn (<2 weeks) and infant (3–14 months) ventricular muscle
strips to changes in pacing frequency. We show that the newborn human ventricle has a flat
FFR that becomes more positive with age. Furthermore, we show alterations in calcium
handling protein and mRNA levels with age as well as developmental changes in cellular
morphology.

MATERIALS AND METHODS

Patients

Ventricular tissue was removed as part of the surgical repair for congenital heart defects and
divided into two age groups: newborns (<2 weeks) and infants (3–14 months). The primary
diagnosis for the newborns was hypoplastic left heart syndrome (HLHS) with ventricle
removed for insertion of a right ventricle to pulmonary artery shunt (table 1). One sample was
left ventricle as noted. The primary diagnosis for the infants was TOF or similar conditions
with ventricle obstructing the right ventricular outflow tract removed. The study protocols were
approved by the Institutional Review Board of Emory University and Children's Healthcare of
Atlanta and determined exempt under 45 CFR 46.101(b)(4).

Isometric contraction measurements

Ventricular tissue was transported to the laboratory in Krebs-Ringer solution containing (in
mM): NaCl 35, KCl 4.75, KH$_2$PO$_4$ 1.2, Na$_2$HPO$_4$ 16, sucrose 134, NaHCO$_3$ 25, glucose 10,
HEPES 10, 2,3-butanedione monoxime (BDM) 30, pH 7.4 with NaOH. Tissue was submerged
in Tyrode's solution containing (mM): NaCl 148.8, KCl 4.0, MgCl$_2$ 5.3, NaH$_2$PO$_4$ 3.3, HEPES
5.0, CaCl$_2$ 0.25, glucose 10 and BDM 30, pH 7.4 with NaOH. Ventricular strips were trimmed
under a dissecting microscope, the width and height at the center of the strip was measured
and cross-sectional area was estimated assuming an oval shape. There was no difference in
cross-sectional area between the two groups (newborn: 1.0±0.2 mm$^2$, n=7, infant: 0.8±0.2
mm$^2$, n=7). After transfer to the recording chamber, strips were fixed at one end and connected
at the other end by a fine suture to a force transducer. The strip was washed for 30–60 minutes
in oxygenated Tyrode's (1.5 mL/min flow, 1.8 mM CaCl$_2$, without BDM) then stimulated at
cycle length (CL) 2000 ms for 30 minutes to stabilize and gradually stretched to achieve
maximum contraction, which was the length set for the experiment. For the FFR, recordings
were made at 30°C with pacing at CLs 2000, 1000, and 500 ms.

Expression of calcium handling proteins

Protein preparation and western blot analysis were performed as we previously described
(17). Tissue was immediately frozen and stored (−80°C) until use. Briefly, tissue was
homogenized in lysis buffer (20mM Hepes containing protease and phosphatase inhibitors
(Sigma)). After low speed centrifugation, the supernatant was centrifuged at 200,000 g (1 hour)
to obtain membrane proteins. Protein concentration was measured using the Bradford method (18). 3 μg membrane or 10 μg total protein was separated on a 12% SDS gel. Each membrane was stained with Ponceau S to confirm equal loading and transfer of proteins. Blots were incubated with antibodies (anti-NCX, anti-SERCA, anti-PLB, Affinity Bioreagents; overnight, 4°C) followed by appropriate HRP-secondary antibody and detection by ECL chemiluminescence (Amersham). Protein bands were quantified by densitometry using ImageJ (NIH).

Determination of mRNA levels

Total RNA was extracted using the RNeasy kit (Qiagen) and reverse transcribed to cDNA using a Super Script III kit with random hexamers (Invitrogen). The quality of each sample was confirmed by Agilent 2100 bioanalyzer. Relative quantification of NCX, SERCA and PLB mRNA levels was performed by real-time RT-PCR (ABI 7500 PCR system) using SYBR Green real-time PCR chemistry (ABI). Specific primers SERCA2a and PLB genes were designed based on GenBank data for human. Predesigned primers for NCX1 were purchased from ABI. The resulting mRNA levels were expressed as a ratio to the level of 18S rRNA (19) and samples in duplicate were used.

Immunostaining of isolated ventricular cells

Ventricular myocytes were isolated as previously described (17). Tissue chunks were stirred at 36°C for 45 min in Krebs-Ringer solution containing 300 IU collagenase/ml (type2, Worthington), 4 IU protease/ml (type XXIV, Sigma) and 1 mg bovine serum albumin/ml, followed by collagenase only until striated cells appeared. Cells were fixed in 4% paraformaldehyde for 10 minutes and stored in 20% sucrose PBS. Plated cells were permeabilized (0.2% Triton), quenched (50 mM NH₄Cl-PBS-Solution), blocked and incubated with primary antibodies overnight (NCX, 1:150 and SERCA, 1:200, ABR) followed by secondary antibody incubation. Cells were imaged using confocal microscopy (Olympus Fluoview).

Statistical analysis

Contractile parameters, mRNA levels and protein levels are reported as mean±SEM and significance was evaluated by t-test or two-way repeated measures ANOVA, followed by Tukey test. P<0.05 indicates statistical significance.

RESULTS

FFR in newborn compared to infant ventricular strips

Table 1 summarizes patient characteristics. Figure 1A shows steady-state developed force for a newborn strip (4 days, top) and for an infant strip (3 months, bottom), with decreasing pacing CL from 2000 to 500 ms. As CL is shortened, developed force does not increase in the newborn but does increase in the infant. The average developed force in newborn muscle strips (n=7) was 1.3±0.3, 1.4±0.3 and 1.1±0.3 mN/mm² at CLs 2000, 1000 and 500 ms, respectively and in infant muscle strips (n=7) was 0.9±0.4, 1.2±0.6 and 1.7±0.9 mN/mm². In the infants, developed force at CL 500 ms was significantly (p<0.05) larger compared to CL 2000 ms. For ease of comparison, we normalized developed force in each strip to that measured at CL 2000 ms. Figure 1B shows the overlay of the contractions for the different CLs. Developed force is not increased at faster stimulation rates in the newborn (top), resulting in a flat FFR. In contrast, the infant has a robust, positive FFR and this is shown in the summary data in figure 2A. At CL 500 ms, the percent increase in developed force is significantly greater in infant compared to newborn. Despite the flat FFR in the newborn, there is a large increase in frequency dependent acceleration of relaxation (FDAR), as seen by shortening of the contraction in figure
1B at shorter CLs. Figures 2B–D show the average for the contraction timing parameters. Total contraction time, time to peak and peak to 90% relaxation significantly decreased with shortening CL in newborn as well as in infant with no difference between age groups. Thus, although there is FDAR of the contraction at both ages, only infants show a positive FFR.

**Developmental changes in calcium handling proteins**

To begin to understand the mechanism of the flat FFR in the newborn human ventricle, we examined mRNA levels of the proteins NCX, SERCA and PLB that are involved in SR calcium uptake (figure 3). In newborns, NCX mRNA is significantly larger than in infants (p=0.003) whereas SERCA mRNA levels did not differ. In contrast, PLB mRNA levels and the PLB/SERCA ratio were smaller in newborns compared to infants.

We examined protein levels by western blot. Figure 4A shows example NCX western blots. From left to right, samples are newborns, young infants (3–6 months) and older infants (6–14 months). Part B shows a significant negative correlation between NCX protein level and increasing age. Both newborns and young infants had significantly higher levels of NCX when compared to older infants (figure 4C). We also examined the protein levels of SERCA (figure 4D–F). Representative blots are shown in part D and linear regression analysis of SERCA as a function of age shows no relation (part E). There were no significant differences in the protein levels when we compared the three age groups (part F). In separate samples (using total protein), we examined the levels of PLB in newborn and older infants and did not find a difference between the two groups (parts G and H). On the same blot, SERCA was also found to be unchanged. Additionally, the PLB/SERCA ratio did not change with age. The determination that SERCA protein levels do not change with development is consistent with mRNA results (figure 3). In contrast, the protein level of PLB and PLB/SERCA ratio did not vary with age, which differs from the mRNA results.

**Immunostaining of NCX and SERCA proteins**

We stained isolated ventricular cells from newborn and infant patients with di-8-ANNEPS and found that the cells from newborns (figure 5A, left) were smaller and lacked transverse (T)-tubules with staining only on the cell surface. Cells from infant ventricle (right) showed a more developed T-tubule system indicated with arrows. NCX staining (red) in a newborn cell (figure 5B, left) shows staining only on the periphery, consistent with the lack of T-tubules (figure 5A). In contrast, NCX is found in the T-tubules as well as the cell surface in infant cells (right). When we examined the localization of SERCA, we saw a regular striated pattern of staining (green, figure 5C) in both the newborn (left) and the infant (right) cells. For part C, the nuclei are stained red. Note that newborn cells were predominantly mononucleated whereas the infant cells had some mononucleated and some binucleated cells. The lack of T-tubules and mononucleated cells seen in the newborn are consistent with a more immature phenotype.

**DISCUSSION**

Very few studies have examined isometric contractions in very young human ventricular tissue. Developed force measured in ventricular strips from patients with TOF (2.5–35 months) was approximately 1.0 mN (1.5 mm wide tissue pieces) (5) which is qualitatively similar to the developed force we report in this study for infant human ventricle (0.9±0.4 mN/mm²). A major finding of this study is that newborn human ventricle has a flat FFR whereas the infant ventricle has a positive FFR (figures 1–2). Animal studies have shown a positive FFR in young mammalian ventricle but did not report changes in the FFR with development (3,20). Comparing immature to adult rabbit papillary muscles, Artman et al.(4) showed a tendency for a smaller FFR in immature tissue, but this result did not reach statistical significance. Cheung et al.(6) measured force frequency curves in children with congenital heart defects.
with noninvasive measurements of contractility using tissue Doppler. They showed a positive FFR in both neonates with transposition of the great arteries with an average age of 11 days and in infants with TOF with an average age of 4.5 months. The difference between that study and our work may be due to the younger age and different pathology of our newborn group or to differences in measurement methodology.

Many investigators have shown a blunted or negative FFR in heart failure (7,8), similar to the differences in newborn and infant human ventricular strips in this study. The positive FFR seen in normal ventricle is likely due to increased calcium influx per unit time (via the L-type calcium channel), resulting in increased SR calcium load (9,21). Decreased levels of SERCA, PLB or the PLB/SERCA ratio have been associated with the blunted FFR seen in heart failure (10–12). A recent study by Quaile et al. (12) in ventricle from pulmonary artery banded felines showed the flat FFR was due to an inability of the SR to increase calcium load in response to increased frequency and was associated with decreased levels of SERCA, PLB and phosphorylated PLB. In the developing rabbit, several studies have shown SERCA (13,14) and PLB (2) increase with postnatal age. We show a similar increase in PLB mRNA and in the ratio of PLB/SERCA mRNA (figure 3). Low levels of PLB in newborn human ventricle may contribute to the flat FFR through depressed function of SERCA. In contrast, we show that the protein levels of SERCA and PLB do not change with age and recent studies in the rabbit have shown that calcium stored in the SR does in fact contribute significantly to the calcium required for contraction (22). Thus, additional studies are required to determine whether the function of the SR is impaired in the newborn human ventricle. Additionally, there is a balance between SR calcium uptake and extrusion of calcium into the extracellular space by NCX. Shifting this balance toward extrusion of calcium by NCX has also been implicated in the blunted FFR in heart failure, is associated with impaired SR function and with elevated NCX levels (7,9). NCX mRNA and protein levels of newborn human ventricle are larger compared to infant ventricle (figures 3–4), consistent with other studies (1,15). Thus, the newborn human ventricle may be more dependent on NCX extrusion to clear calcium from the cytosol, resulting in lower dependence on the SR, which may lead to the blunted FFR.

Changes in the FFR may also be due to alterations in myofilaments with development. α-skeletal actin increases with postnatal development and may alter contractility (23). Shortly after birth, troponin I switches from the slow skeletal to the faster cardiac isoform which correlates with increases in tension and decrease in calcium sensitivity (24). Decreased calcium sensitivity with development has also been correlated with changes in isoforms of troponin T (25). Nassar et al. (26) suggested that the greater relative internal load compared to contractile elements in newborn ventricular cells may contribute to decreased contractility in the newborn rabbit. Thus, developmental changes in myofilaments and associated proteins may contribute to the depressed FFR seen in our newborn group. Further studies are needed to evaluate these differences as a mechanism for the flat FFR in the newborn human ventricle.

Note that we show that increasing pacing frequency accelerates relaxation of contraction in both newborn and infant human ventricle (figure 2). Others have shown that relaxation of the mammalian ventricle increases with development (1,27) and may be due to increases in SERCA levels and activity (13,14). It is possible that changes in relaxation rates were not seen in the present study due to the limited age range of the two groups. In the adult, calcium/calmodulin-dependent kinase II (CamKII) may be involved in FDAR (28,29), but the role of CamKII remains controversial (30). Recently, Huke and Bers (29) showed that the time course of FDAR is faster than the time course of CamKII-dependent phosphorylation of PLB and ryanodine receptor and conclude that neither underlies the mechanism of FDAR. An alternative mechanism for FDAR in newborn human may be shortening of action potential duration which has been shown to contribute to enhanced relaxation (31). We have not recorded action potentials simultaneously with contractions in this study, but such work would provide
important information as to the mechanism of FDAR in the newborn. An additional mechanism of FDAR could be increased extrusion of calcium by NCX due to calcium accumulation in the subsarcolemal space at higher frequencies of pacing, thus increasing the rate of the exchanger (32). Hasenfuss et al. (8) showed in a study of heart failure patients that ventricle from patients with little diastolic dysfunction had increased levels of NCX and unchanged SERCA levels and demonstrated FDAR. In contrast, ventricular tissue with diastolic dysfunction had unchanged NCX, decreased SERCA levels, and did not demonstrate FDAR. These results suggest that increased NCX levels seen in our newborn group may contribute to FDAR.

Postnatal changes in ventricular cellular morphology have been shown in several species. In newborn rabbit ventricular cells, T-tubules are sparse and are partially developed at 10 days after birth (33). Newborn human ventricular cells also have sparse T-tubules that develop over the first year of life (figure 5). In rabbit, T-tubule development correlates with development of a more spatially homogeneous calcium transient (33). Furthermore, several studies have shown that NCX is located only on the periphery in newborn rabbit cells and becomes more central and aligns with the T-tubules with postnatal development (33,34). We show that NCX is found only on the periphery of the newborn human ventricular cells but has a more striated pattern in the infant cells. Furthermore, the spatial organization of SERCA was similar in both the newborn and infant cells and similar to that seen in adult rabbit (13). We also found that newborn human cells were primarily mononucleated, whereas infant cells had a mix of mononucleated and binucleated cells (figure 5C). Schmid and Pfitzer (35) found that near the time of birth in human right ventricle, only 11% of the cells were binucleated and that this increased to 42% by one year of age. Postnatal development has been shown in to include a transformation from mononucleated to bi- or multinucleated myocytes (36).

We cannot definitively say that the changes in the FFR between newborn and infant ventricle are due to the different developmental ages of the patients and not due to the different dominant pathology of the two age groups (HLHS vs. TOF). However, there are several pieces of evidence, mirroring work in other mammalian species that suggests the difference in the FFR between newborns and infants is due to their different developmental age. In particular, we show a linear decrease in NCX levels from newborns to young infants to older infants (figure 4). Furthermore, we show development of T-tubules and appearance of binucleated cells with increasing age (figure 5).

In summary, we have shown for the first time that the newborn human ventricle has a blunted FFR that improves during the early postnatal period. The blunted FFR may be due to decreased SR calcium load due to competition between NCX and SERCA for clearing calcium from the cytoplasm. The level of NCX is higher in the newborn compared to the infant and cellular changes between the newborn and infant human ventricle are consistent with those seen in animal models of development. A better understanding of developmental changes in contractility in human ventricle is critically important for developing therapies that are specific for the pediatric cardiac patient. In particular, as pediatric cardiac surgery is increasingly done in the first year of life, with concomitant issues of arrhythmias and ventricular failure, the need for understanding calcium regulation in this age group is becoming increasingly important.

Acknowledgments

Financial Support: This work was supported by National Heart, Lung and Blood Institute Grants HL-088488 (MBW) and HL-077485 (RWJ), and American Heart Association Southeast Affiliate Grant in Aid 0755537B (MBW) and by financial support from Children’s Healthcare of Atlanta.
Abbreviations
CamKII, calcium/calmodulin-dependent kinase II; CL, cycle length; FDAR, frequency dependent acceleration of relaxation; FFR, force frequency relationship; HLHS, hypoplastic left heart syndrome; NCX, Na/Ca exchanger; PLB, phospholamban; SERCA, SR calcium-ATPase; SR, sarcoplasmic reticulum; TOF, tetralogy of Fallot.

REFERENCES


Figure 1.
Contractions measured in ventricular tissue strips. A. Developed force from a newborn (4 days old, top panel) and an infant (3 months old, bottom panel) strip. The pacing cycle length (CL) decreased from 2000 to 1000 and 500 ms. Steady state contractions are shown and the dashed line indicates the amplitude of developed force at CL 2000 ms. B. Developed force as in A, but normalized to the amplitude at CL 2000 ms (black line) with CL 1000 ms (red) and CL 500 ms (blue) overlaid.
Figure 2.
Average data for contractions from newborn and infant ventricular tissue strips are shown. A. Average developed force expressed as percent of CL 2000 ms for newborn (open, n=7, 4 patients) and infant (shaded, n=7, 6 patients) ventricle (*p<0.05). B. Total contraction time, C. Time to peak and D. Peak to 90% relaxation time for newborn (open) and infant (shaded) ventricular strips (*, p<0.05 compared to CL 2000 ms, §, p<0.05 compared to CL 1000 ms).
Figure 3.
mRNA levels (normalized to 18S rRNA) of calcium handling proteins change with developmental age. Newborn (open, n=6) and infant (shaded, n=5) levels of NCX (Na/Ca exchanger), SERCA (SR Ca-ATPase pump) and PLB (phospholamban) as well as the PLB/SERCA ratio are shown. *, p<0.05.
Figure 4.
Protein levels of calcium handling proteins in the developing human ventricle. A. Example of western blots for NCX (Na/Ca exchanger). Lanes are labeled with age of patient (d=days, m=months) with newborns furthest left, young infants in the center and older infants furthest right. B. Density of NCX plotted as a function of age (newborns, solid triangles; young infants, open circles; older infants, solid circles), showing an inverse linear relationship (R=−0.66, p=0.003) between NCX protein levels and age. C. Average NCX protein levels for the three age groups: newborn (open, n=6), young infants (hashed and shaded, n=6) and older infants (shaded, n=6). *, p<0.05. D. Western blots of SERCA (SR Ca-ATPase pump) labeled with ages as in (A). E. Density of SERCA plotted as a function of age ((R=−0.11, p=n.s.). F. Average SERCA levels for the three age groups (n=6 for each age). Parts A–F used membrane proteins. G. Western blots using total proteins of SERCA, phospholamban (PLB) and GAPDH for loading control. H. Summary data for part G, normalized to GAPDH (n=6 newborn and n=5 infant).
Figure 5.
Morphological analysis of ventricular cells isolated from ventricle from newborn and infant patients. A. Single ventricular cells from a newborn (left, 7 days) and an infant (right, 5 mos.) with the membrane of the cells labeled with di-8-ANNEPS. Arrows indicate partial T-tubule development in infant cell. B. Immunostaining of ventricular cells for Na/Ca exchange (NCX) in newborn (left, 6 days) and infant (right, 7 mos.). C. Immunostaining of newborn (left) and infant (right) ventricular cells with SR Ca-ATPase pump (SERCA, green) and nuclear staining (red).
### Table 1

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Age</th>
<th>Gender</th>
<th>Race</th>
<th>Diagnosis</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>3 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>1, 2</td>
</tr>
<tr>
<td>3</td>
<td>3 d</td>
<td>M</td>
<td>AA</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>3 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>4 d</td>
<td>F</td>
<td>AA</td>
<td>TOF</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>4 d</td>
<td>M</td>
<td>AA</td>
<td>HLHS</td>
<td>1, 2</td>
</tr>
<tr>
<td>7</td>
<td>4 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>4 d</td>
<td>F</td>
<td>C</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>4 d</td>
<td>M</td>
<td>AA</td>
<td>HLHS</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>5 d</td>
<td>M</td>
<td>MR</td>
<td>HLHS</td>
<td>1, 2</td>
</tr>
<tr>
<td>11</td>
<td>6 d</td>
<td>M</td>
<td>AA</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>6 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>&lt;7 d</td>
<td>M</td>
<td>H</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>&lt;7 d</td>
<td>F</td>
<td>C</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>15</td>
<td>&lt;7 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>16</td>
<td>&lt;7 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>7 d</td>
<td>M</td>
<td>C</td>
<td>DILV</td>
<td>4 (LV)</td>
</tr>
<tr>
<td>18</td>
<td>7 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>7 d</td>
<td>M</td>
<td>C</td>
<td>HLHS</td>
<td>3</td>
</tr>
<tr>
<td>20</td>
<td>13 d</td>
<td>F</td>
<td>C</td>
<td>HLHS</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>14 d</td>
<td>M</td>
<td>C</td>
<td>DILV</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>16 d</td>
<td>M</td>
<td>AA</td>
<td>HLHS</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Age</th>
<th>Gender</th>
<th>Race</th>
<th>Diagnosis</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>3 m</td>
<td>F</td>
<td>C</td>
<td>DORV</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>3 m</td>
<td>F</td>
<td>NS</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>25</td>
<td>3 m</td>
<td>M</td>
<td>H</td>
<td>DORV</td>
<td>1</td>
</tr>
<tr>
<td>26</td>
<td>3 m</td>
<td>F</td>
<td>C</td>
<td>TOF</td>
<td>3</td>
</tr>
<tr>
<td>27</td>
<td>3 m</td>
<td>M</td>
<td>C</td>
<td>TOF</td>
<td>3</td>
</tr>
<tr>
<td>28</td>
<td>3.5 m</td>
<td>M</td>
<td>C</td>
<td>TOF</td>
<td>3</td>
</tr>
<tr>
<td>29</td>
<td>4.5 m</td>
<td>F</td>
<td>AA</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>30</td>
<td>4.5 m</td>
<td>F</td>
<td>AA</td>
<td>TOF</td>
<td>1, 3</td>
</tr>
<tr>
<td>31</td>
<td>5 m</td>
<td>M</td>
<td>NS</td>
<td>TOF</td>
<td>4</td>
</tr>
<tr>
<td>32</td>
<td>5 m</td>
<td>M</td>
<td>NS</td>
<td>DORV, PS</td>
<td>1</td>
</tr>
<tr>
<td>33</td>
<td>5.5 m</td>
<td>M</td>
<td>C</td>
<td>TOF</td>
<td>3</td>
</tr>
<tr>
<td>34</td>
<td>6 m</td>
<td>F</td>
<td>AA</td>
<td>DORV, PS, Down's</td>
<td>3</td>
</tr>
<tr>
<td>35</td>
<td>6 m</td>
<td>M</td>
<td>C</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>36</td>
<td>7 m</td>
<td>F</td>
<td>C</td>
<td>TOF</td>
<td>4</td>
</tr>
<tr>
<td>37</td>
<td>7 m</td>
<td>M</td>
<td>C</td>
<td>DCRV, VSD</td>
<td>1</td>
</tr>
<tr>
<td>38</td>
<td>7 m</td>
<td>M</td>
<td>AA</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>39</td>
<td>7 m</td>
<td>F</td>
<td>AA</td>
<td>TOF</td>
<td>3</td>
</tr>
<tr>
<td>40</td>
<td>7 m</td>
<td>F</td>
<td>AA</td>
<td>VSD, PS, TGA</td>
<td>1</td>
</tr>
<tr>
<td>41</td>
<td>7.5 m</td>
<td>F</td>
<td>C</td>
<td>TOF, CAVC</td>
<td>2</td>
</tr>
<tr>
<td>42</td>
<td>8 m</td>
<td>F</td>
<td>AA</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>43</td>
<td>8 m</td>
<td>M</td>
<td>AA</td>
<td>PA, VSD</td>
<td>1</td>
</tr>
<tr>
<td>44</td>
<td>9 m</td>
<td>M</td>
<td>C</td>
<td>VSD, DCRV</td>
<td>2</td>
</tr>
<tr>
<td>45</td>
<td>10 m</td>
<td>M</td>
<td>AA</td>
<td>TOF</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>10 m</td>
<td>M</td>
<td>NS</td>
<td>TOF</td>
<td>2</td>
</tr>
<tr>
<td>47</td>
<td>11 m</td>
<td>M</td>
<td>AS</td>
<td>VSD, RVOTO</td>
<td>1</td>
</tr>
<tr>
<td>48</td>
<td>12 m</td>
<td>M</td>
<td>AA</td>
<td>TOF</td>
<td>1</td>
</tr>
<tr>
<td>49</td>
<td>12 m</td>
<td>M</td>
<td>AA</td>
<td>VSD, DORV, RVOTO</td>
<td>1</td>
</tr>
<tr>
<td>50</td>
<td>14 m</td>
<td>M</td>
<td>AA</td>
<td>TOF</td>
<td>1, 2</td>
</tr>
<tr>
<td>51</td>
<td>14 m</td>
<td>M</td>
<td>AA</td>
<td>TOF</td>
<td>1</td>
</tr>
</tbody>
</table>

**Race**: NS, Not Specified; C, Caucasian; AA, African American; H, Hispanic; MR, Multi-Racial; AS, Asian

**Diagnosis**: HLHS, Hypoplastic Left Heart Syndrome; TOF, Tetralogy of Fallot; DILV, Double Inlet Left Ventricle; DORV, Double Outlet Right Ventricle; PS, Pulmonary Stenosis; PA, Pulmonary Atresia; TGA, Transposition of the Great Arteries; DCRV, Double Chamber Right Ventricle; CAVC, Complete Atrio-Ventricular Canal; RVOTO, Right Ventricular Outflow Tract Obstruction; Down’s, Down’s Syndrome.

**Use**: 1, protein; 2, mRNA; 3, contraction measurements; 4, cell isolation